DOI:
10.1055/s-00000045
Der Nuklearmediziner
LinksClose Window
References
Nilsson S, Franzén L, Parker C. et al.
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Lancet Oncol 2007;
8: 587-594
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.